Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Martin Edwards Biography and Net Worth

Director of Verona Pharma

Dr Edwards has significant experience in investing and contributing to the development of biotech companies in both Europe and the US. Dr Edwards currently serves on the boards of Inozyme Pharma, Morphic Therapeutic and Reata Pharmaceuticals. Previously, he was Senior Partner at Novo Ventures from 2003-2020, and Corporate VP and Global Head of Drug Development for Novo Nordisk, where he led all aspects of pre-clinical and clinical drug development. Dr Edwards trained in physiology and medicine at the University of Manchester. He was elected a Member of the Royal College of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds a MBA from the University of Warwick.

What is Martin Edwards' net worth?: The estimated net worth of Martin Edwards is at least $2.24 million as of November 20th, 2023. Dr. Edwards owns 144,800 shares of Verona Pharma stock worth more than $2,240,056 as of April 28th. This net worth evaluation does not reflect any other investments that Dr. Edwards may own. Learn More about Martin Edwards' net worth.
How do I contact Martin Edwards?: The corporate mailing address for Dr. Edwards and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Martin Edwards' contact information.
Has Martin Edwards been buying or selling shares of Verona Pharma?: Martin Edwards has not been actively trading shares of Verona Pharma in the last ninety days. Most recently, on Monday, November 20th, Martin Edwards bought 33,736 shares of Verona Pharma stock. The stock was acquired at an average cost of $1.84 per share, with a total value of $62,074.24. Following the completion of the transaction, the director now directly owns 144,800 shares of the company's stock, valued at $266,432. Learn More on Martin Edwards' trading history.
Who are Verona Pharma's active insiders?: Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.
Are insiders buying or selling shares of Verona Pharma?: In the last year, Verona Pharma insiders bought shares 2 times. They purchased a total of 193,736 shares worth more than $378,874.24. In the last year, insiders at the sold shares 19 times. They sold a total of 2,164,281 shares worth more than $13,411,301.36. The most recent insider tranaction occured on November, 20th when Director Martin Edwards bought 33,736 shares worth more than $62,074.24. Insiders at Verona Pharma own 4.8% of the company. Learn More about insider trades at Verona Pharma.
Information on this page was last updated on 11/20/2023.

Martin Edwards Insider Trading History at Verona Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/20/2023	Buy	33,736	$1.84	$62,074.24	144,800

Martin Edwards Buying and Selling Activity at Verona Pharma

Verona Pharma Company Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Today's Range

Now: $15.47

$15.25

$15.60

50 Day Range

MA: $16.34

$15.24

$18.19

2 Week Range

Now: $15.47

$11.83

$23.81

Volume

260,511 shs

Average Volume

413,627 shs

Market Capitalization

$1.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4